All In Biotech

Drug Trial Radar · NCT05089084

Study of ARO-APOC3 (Plozasiran) in Adults With Familial Chylomicronemia Syndrome (FCS)

A Phase 3 Study to Evaluate the Efficacy and Safety of ARO-APOC3 in Adults With Familial Chylomicronemia Syndrome

Last checked: Nov 19, 2026Latest source record: Jun 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

75

Actual

Start

Dec 14, 2021

Primary completion

Apr 29, 2024

Study completion Apr 21, 2026

Sponsor

Lead sponsor
Arrowhead PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Oct 22, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of AROAPOC3-3001 is to evaluate the efficacy and safety of ARO-APOC3 (plozasiran) in adult participants with familial chylomicronemia syndrome (FCS). Participants who have met all eligibility criteria will be randomized to receive 4 doses of plozasiran or matching placebo administered subcutaneously. Participants who complete the randomized period will continue in a 2-year open-label extension period where all participants will receive plozasiran.

Conditions

  • Familial Chylomicronemia

Interventions

  • PlozasiranDrug

    ARO-APOC3 subcutaneous (SC) injection

  • PlaceboDrug

    sterile normal saline (0.9% NaCl) SC injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Change From Baseline at Month 10 in Fasting Triglycerides (TG)Time frame: Baseline, Month 10

Locations

58 sites in 21 countries. Site status is shown where the registry gives one.

  • Clinical Site 1

    Boca Raton, Florida

  • Clinical Site 2

    Suwanee, Georgia

  • Clinical Site 3

    Indianapolis, Indiana

  • Clinical Site 4

    Elkridge, Maryland

  • Clinical Site 5

    St Louis, Missouri

  • Clinical Site 7

    New York, New York

  • Clinical Site 6

    New York, New York

  • Clinical Site 8

    Austin, Texas

  • Clinical Site 9

    Norfolk, Virginia

  • Clinical Site 10

    Córdoba, Argentina

  • Clinical Site 11

    Formosa, Argentina

  • Clinical Site 12

    Melbourne, Australia

  • Clinical Site 13

    Nedlands, Australia

  • Clinical Site 14

    Camperdown, New South Wales, Australia

  • Clinical Site 15

    St Leonards, New South Wales, Australia

  • Clinical Site 16

    Melbourne, Victoria, Australia

  • Clinical Site 17

    Graz, Austria

  • Clinical Site 18

    Edegem, Belgium

  • Clinical Site 19

    Ghent, Belgium

  • Clinical Site 20

    Leuven, Belgium

  • Clinical Site 21

    Liège, Belgium

  • Clinical Site 22

    London, Ontario, Canada

  • Clinical Site 23

    Toronto, Ontario, Canada

  • Clinical Site 24

    Chicoutimi, Quebec, Canada

  • Clinical Site 25

    Montreal, Quebec, Canada

  • Clinical Site 26

    Québec, Quebec, Canada

  • Clinical Site 27

    Zagreb, Croatia

  • Clinical Site 28

    Paris, France

  • Clinical Site 29

    Marseille, Cedez 05, France

  • Clinical Site 30

    Jena, Germany

  • Clinical Site 31

    Leipzig, Germany

  • Clinical Site 32

    Galway, Ireland

  • Clinical Site 33

    Jerusalem, Israel

  • Clinical Site 34

    Chiba, Japan

  • Clinical Site 35

    Ishikawa, Japan

  • Clinical Site 36

    Osaka, Japan

  • Clinical Site 37

    Tochigi, Japan

  • Clinical Site 38

    Tokyo, Japan

  • Clinical Site 39

    Tokyo, Japan

  • Clinical Site 40

    Mexico City, Mexico

Showing 40 of 58 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.